Rituximab for granulomatous lymphocytic interstitial lung disease in a patient with common variable immunodeficiency. Is single therapy enough?
Journal Title: International Journal of Clinical Rheumatology - Year 2018, Vol 13, Issue 1
Abstract
Abstract: Granulomatous Lymphocytic Interstitial Lung Disease (GLILD) is an inflammatory pulmonary complication of common variable immunodeficiency (CVID) with distinctive patterns in the biopsy; Granulomatous Disease, Lymphocytic Interstitial Disease, Follicular Bronchiolitis and Organizing Pneumonitis. Without the proper treatment this complication will lead to important pulmonary dysfunction due to fibrosis. Although this process has been well recognized, protocols for a standardized treatment, and the proper timing for the use of immune modulation as well as the maintenance time with monoclonal antibodies are an unclear topic. Case presentation: We present the case of a 57-year-old female patient with CVID. During the evaluation of an episode of autoimmune hemolytic anemia, she presented concomitantly radiological and histopathological features of GLILD. She was treated successfully with Rituximab monotherapy without any complications and is currently asymptomatic. Conclusion: We conclude that the use of Rituximab as single therapy, modulates the lymphocytic infiltration of the lung parenchyma and stops the progression and organization of the damage mediated by B cells and indirectly by T cells, and it could be used as monotherapy in the proper timing of the diagnostic process.
Authors and Affiliations
Mauricio Arraya
Keywords
Related Articles
- EP ID EP604298
- DOI -
- Views 66
- Downloads 0
Hyperuricemia as an independent predictor and prognostic factor in the development of lupus nephritis
Background: Lupus nephritis (LN) can increase morbidity and mortality risk in systemic lupus erythematosus (SLE) and 25% of the patients with LN will advance to end-stage renal disease. Objective: To evaluate if hyperuri...
Nanomedicine in rheumatology: A new field in the diagnosis and therapy of rheumatic diseases
Nanomedicine is a prolific and vastly expanding field of medicine rendering important new avenues to improve diagnosis and treatment of human maladies. However, safety of the nanomaterials and therapeutic agents must be...
An unusual presentation of inflammatory myopathy in a patient on natalizumab treatment for multiple sclerosis: A case report and review of myopathological classification of inflammatory myopathy
Acquired immune and inflammatory myopathies (IIMs) are traditionally subdivided into dermatomyositis, polymyositis, inclusion body myositis (IBM) and necrotizing autoimmune myopathy (NAM). Our patient is a 38-year old fe...
A case series of malignancies: mimics of Rheumatological disorders
Background: Malignancy and Autoimmunity interplay is full of complexities. We here, describe few cases of malignancies presented as mimics of autoimmune disorders. A case of acute myeloid leukaemia had leukocytoclastic v...
IL-17 in primary knee osteoarthritis and its relation with severity of the disease
Objective: Is to measure serum level of interleukin 17 and correlate its level with disease severity in patients with primary knee OA. Methods: Serum was collected from patients with primary knee osteoarthritis and age-...